Pulmatrix (PULM) Income from Continuing Operations (2013 - 2026)
Pulmatrix (PULM) posted Income from Continuing Operations of 1330000.0 for Q1 2026, up 95.37% sequentially from 28737000.0 in Q4 2025, and up 27.12% YoY from 1046228.45 in Q1 2025.
Pulmatrix (PULM) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Pulmatrix has reported Income from Continuing Operations for 14 years, with the latest figure at 1330000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 27.12% year-over-year to 1330000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 32454000.0 (down 162.28% YoY) and the FY2025 annual result came in at 32874000.0, down 229.5% from the prior year.
- Income from Continuing Operations rose to 1330000.0 in Q1 2026 per PULM's latest filing, from 28737000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 846000.0 in Q3 2025 and troughed at 28737000.0 in Q4 2025.
- A 5-year average of 5702000.0 and a median of 4757000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 86.47% in 2025, down 1429.38% in 2025.
- Over 5 years, Income from Continuing Operations stood at 4757000.0 in 2022, then surged by 55.5% to 2117000.0 in 2023, then climbed by 11.24% to 1879000.0 in 2024, then slumped by 1429.38% to 28737000.0 in 2025, then soared by 95.37% to 1330000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 1330000.0, 28737000.0, and 846000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | -1.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.09 Mn |
| Mar 31, 2026 | -1.33 Mn |
| Dec 31, 2025 | -28.74 Mn |
| Sep 30, 2025 | -846,000.00 |
| Jun 30, 2025 | -1.54 Mn |
| Mar 31, 2025 | -1.83 Mn |
| Dec 31, 2024 | -1.88 Mn |
| Sep 30, 2024 | -2.58 Mn |
| Jun 30, 2024 | -6.09 Mn |
| Mar 31, 2024 | -13.49 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Sep 30, 2023 | -6.64 Mn |
| Jun 30, 2023 | -4.42 Mn |
| Mar 31, 2023 | -5.02 Mn |
| Dec 31, 2022 | -4.76 Mn |
| Sep 30, 2022 | -5.53 Mn |
| Jun 30, 2022 | -4.87 Mn |
| Mar 31, 2022 | -5.27 Mn |
| Dec 31, 2021 | -4.34 Mn |
| Sep 30, 2021 | -8.49 Mn |